FDA Cracks Down on Diabetes Marketing

Diabetes Forecast: November 2013

Diexi. Diaberex. Glytain. Glucocil. Nepretin. They sound like medications your doctor might prescribe for treating diabetes. But they’re not. In July, the Food and Drug Administration (FDA) issued letters to 15 companies warning them that their mislabeled products were violating federal law. The FDA requested written responses within 15 days detailing how the companies would correct the violations. If they didn’t respond, the FDA had the right to take action, including seizure and criminal prosecution.

“Bogus products for diabetes are particularly troubling because there are effective options available to help manage this serious disease rather than exposing patients to unproven and risky products,” Gary Coody, RPh, national health fraud coordinator for the FDA, said in a statement. The FDA worries that failure to follow established treatment plans can lead to serious health problems and possibly death. Read More